CD38 and neoplasm: Because of its distinctive design and diverse modes of action, the CD38/CD47 BsAb has the potential to augment antitumor efficacy in individuals with CD38+ malignancies in comparison to anti-CD38 mAbs by effectively addressing primary and acquired tumor escape mechanisms of resistance.